Pasricha, Sant-Rayn http://orcid.org/0000-0002-5502-0434
Lim, Pei Jin
Duarte, Tiago L. http://orcid.org/0000-0002-4901-4580
Casu, Carla
Oosterhuis, Dorenda
Mleczko-Sanecka, Katarzyna
Suciu, Maria
Da Silva, Ana Rita
Al-Hourani, Kinda
Arezes, João
McHugh, Kirsty
Gooding, Sarah
Frost, Joe N.
Wray, Katherine
Santos, Ana
Porto, Graça
Repapi, Emmanouela
Gray, Nicki
Draper, Simon J. http://orcid.org/0000-0002-9415-1357
Ashley, Neil
Soilleux, Elizabeth
Olinga, Peter
Muckenthaler, Martina U.
Hughes, Jim R. http://orcid.org/0000-0002-8955-7256
Rivella, Stefano
Milne, Thomas A. http://orcid.org/0000-0002-0413-4271
Armitage, Andrew E.
Drakesmith, Hal
Article History
Received: 18 November 2016
Accepted: 4 July 2017
First Online: 1 September 2017
Competing interests
: Professor Drakesmith declares research funding from Pfizer and consultancy with Kymab. Professor Draper declares research funding from Pfizer. Professor Rivella declares consultancies for Novartis and Ionis. Professor Milne is a shareholder of Oxstem Oncology (OSO), a subsidiary company of OxStem Ltd. The remaining authors declare no competing financial interests.